Baird lowered the firm’s price target on DexCom (DXCM) to $82 from $90 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results where its quality issues appear to be resolved but it impacted new starts and gross margins.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom price target lowered to $85 from $109 at BTIG
- Dexcom Faces Challenges with G7 Device: Hold Rating Amidst Investor Caution
- DexCom price target lowered to $75 from $100 at Piper Sandler
- DexCom price target lowered to $75 from $85 at Citi
- DexCom price target lowered to $93 from $98 at Wells Fargo